Multiple Myeloma Clinical Trial Landscape

Why multiple myeloma trial monitoring matters

Multiple myeloma is one of the most therapeutically active disease areas in oncology. The pipeline is large and evolving rapidly (the live trial data on this page shows today's active count), driven by transformative modalities like CAR-T cell therapy, bispecific T-cell engagers, and next-generation immunomodulatory agents.

For pharma business development teams and biotech investors, the pace of innovation in myeloma makes manual monitoring impractical. Key signals to track:

• New CAR-T programs targeting BCMA, GPRC5D, and FcRH5, the most competitive space in hematology
• Bispecific antibody trials (teclistamab, elranatamab, talquetamab competitors and next-gen programs)
• Cereblon E3 ligase degrader (CELMoD) programs moving beyond first-generation lenalidomide/pomalidomide
• Combination regimen trials pairing novel agents with established backbones (daratumumab, carfilzomib)
• Trials in newly diagnosed vs. relapsed/refractory settings, different competitive dynamics
• Status changes: Phase 2 to Phase 3 transitions, clinical holds, and voluntary terminations

What we monitor for multiple myeloma

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a myeloma watch profile, you can configure:

• Condition keywords: "multiple myeloma", "plasma cell myeloma", "smoldering myeloma", "BCMA", "GPRC5D", "CAR-T myeloma"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors (including NCI cooperative groups)
• Status filter: Recruiting only, all active studies, or any status including completed/terminated

Phase 3 pipeline: selected recruiting trials

The Phase 3 myeloma landscape is dominated by bispecific antibody combination trials, next-generation CAR-T programs, and CELMoD agents. Selected currently recruiting Phase 3 studies:

This table is a snapshot. DataLookout monitors the active Phase 3 myeloma trials daily and tells you the next morning when any record changes, status update, enrollment count, primary completion date.

The myeloma competitive landscape in 2026

Multiple myeloma has seen an explosion of therapeutic innovation in recent years. The competitive intelligence challenge is keeping track of the shifting landscape across four key modalities:

CAR-T cell therapy: next generation

Following approvals of idecabtagene vicleucel (Abecma, ide-cel) and ciltacabtagene autoleucel (Carvykti, cilta-cel), both targeting BCMA, the CAR-T space is entering its second generation. AstraZeneca's AZD0120 is a dual-targeting CAR-T (BCMA + GPRC5D) now in Phase 3, addressing the resistance that emerges when BCMA expression is lost. Kite/Gilead's anitocabtagene autoleucel and BMS/Juno's BMS-986393 are also in Phase 3, competing directly with approved cilta-cel. All three programs filed their Phase 3 trials in 2024-2025, signaling aggressive timelines to approval.

Bispecific antibodies: three approved, more in Phase 3

Three BCMA-targeting bispecifics are now approved or in late-stage development: teclistamab (Tecvayli, J&J), elranatamab (Elrexfio, Pfizer), and AbbVie's etentamig. A fourth class, GPRC5D × CD3 (talquetamab, Talvey) and FcRH5 × CD3 (linvoseltamab, Sanofi/Regeneron), is now also in Phase 3. The key competitive question is which bispecifics win in combination: J&J has Phase 3 trials testing teclistamab + talquetamab together (NCT06208150), betting that combining two non-competing bispecifics produces deeper responses. This "bispecific doublet" approach could define the standard of care in relapsed/refractory myeloma by 2027.

CELMoD agents: replacing lenalidomide

Cereblon E3 ligase modulatory drugs (CELMoDs) are designed to overcome resistance to lenalidomide and pomalidomide. BMS has two CELMoD programs in Phase 3: mezigdomide (SUCCESSOR-2, NCT05519085) and iberdomide (NCT05827016, in the maintenance setting). If either succeeds, CELMoDs become the new IMiD backbone, displacing lenalidomide in newly diagnosed and maintenance protocols where lenalidomide has dominated for a decade.

Novel targets: GPRC5D, FcRH5, and CD38

The myeloma antigen landscape has expanded beyond BCMA. GPRC5D (talquetamab) is now approved and in Phase 3 combinations. FcRH5 (linvoseltamab) is in Phase 3 vs. standard of care. Daratumumab (CD38) remains the dominant combination backbone with 29 active trials. The next generation is exploring combinations of all three classes simultaneously, daratumumab + bispecific + CELMoD triplets and quadruplets that would have been unimaginable five years ago.

Who uses myeloma trial monitoring

Pharma business development teams

BD teams at companies with myeloma programs track competitor trial activity daily. A new Phase 2 CAR-T program from an emerging biotech could represent a licensing opportunity, or a competitive threat. Knowing the day it's registered gives you a head start.

Biotech investors and analysts

Hematology-focused investors monitor trial starts and status changes as leading indicators of pipeline value. A Phase 3 initiation in frontline myeloma signals a major commitment of capital and de-risks the asset for potential investors.

Clinical research organizations (CROs)

CROs specializing in hematology track new trial registrations to identify sponsor companies entering active clinical development, prospective clients who will need site management, patient recruitment, and data management services.

Patient advocacy organizations

Myeloma patient organizations like the International Myeloma Foundation and the Multiple Myeloma Research Foundation track recruiting trials to help patients access the latest therapies through clinical trial participation.

Frequently asked questions